ライフサイエンスコーパス: sentinel lymph node

1 bular carcinoma, 1 invasive papilloma, and 4 sentinel lymph nodes).

2 tastatic disease correctly identified in the sentinel lymph node.

3 ected by immunohistochemical analysis of the sentinel lymph node.

4 ve nodes, 36 of whom had at least one mapped sentinel lymph node.

5 ients had successful mapping of at least one sentinel lymph node.

6 hese, 72 (79%) had metastases in the hottest sentinel lymph node.

7 ts and 19 of 91 patients (21%) with positive sentinel lymph nodes.

8 (IQR 4.1-8.0) for the patients with positive sentinel lymph nodes.

9 Micrometastasis was detected in 1 of 5 sentinel lymph nodes.

10 atic system to these intramammary in-transit sentinel lymph nodes.

11 iposomes specific for lymph vessels from the sentinel lymph nodes.

12 gene expression in metastatic lesions within sentinel lymph nodes.

13 nificance of colon cancer micrometastasis in sentinel lymph nodes.

14 decreased VEGF-A would limit angiogenesis in sentinel lymph nodes.

15 he promotion of cancer metastasis beyond the sentinel lymph nodes.

16 rs that mediate their efficient transport to sentinel lymph nodes.

17 chnique's potential beyond merely localizing sentinel lymph nodes.

18 lap in tumor-involved relative to tumor-free sentinel lymph nodes.

19 Ninety-one patients (19%) had positive sentinel lymph nodes.

20 0 pmol of near-infrared quantum dots permits sentinel lymph nodes 1 cm deep to be imaged easily in re

21 In patients with negative sentinel lymph nodes, 11% developed metastases beyond th

22 B7-H3 expression was highly correlated to sentinel lymph node and overall number of lymph nodes wi

23 rtant role in promoting cancer metastasis to sentinel lymph nodes and beyond and also promotes organ

24 Association of SNTI in sentinel lymph nodes and BMM in patients with stage I to

25 isolated tumor cells and micrometastases) in sentinel lymph nodes and bone marrow micrometastases (BM

26 oma metastases in the hottest and nonhottest sentinel lymph nodes and factors that correlate with dis

27 atric patients more frequently have positive sentinel lymph nodes and increased tumor thickness, yet

28 The mechanisms of tumor metastasis to the sentinel lymph nodes are poorly understood.

29 The primary endpoint, sensitivity of the sentinel-lymph-node-based detection of metastatic diseas

30 h nodes, 11% developed metastases beyond the sentinel lymph node basin and 3.4% recurred in the basin

31 ammation; the results clearly identified the sentinel lymph node basin and delineated the lymphatic d

32 There was a higher proportion of sentinel lymph node biopsies (SLNB) performed by high-vo

33 Digital images of sentinel lymph node biopsies from 56 patients with small

34 change in approach to patients with positive sentinel lymph node biopsies has increased the complexit

35 000-microCi dose of I methylene blue dye for sentinel lymph node biopsies.

36 ial mastectomy (PM), partial mastectomy with sentinel lymph node biopsy (PM SLNB), laparoscopic chole

37 Sentinel lymph node biopsy (SLN) is an accepted alternat

38 Observations: Sentinel lymph node biopsy (SLNB) after NAC in patients

39 y lymph node assessment (ALNA) consisting of sentinel lymph node biopsy (SLNB) alone if sentinel lymp

40 that disconcerting lymphedema rates in both sentinel lymph node biopsy (SLNB) and axillary lymph nod

41 oscintigraphy is standardly performed before sentinel lymph node biopsy (SLNB) for breast cancer.

42 Guidelines recommend sentinel lymph node biopsy (SLNB) for patients with clin

43 The validity of sentinel lymph node biopsy (SLNB) for T1 or T2, clinical

44 Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are

45 evaluate the sensitivity and specificity of sentinel lymph node biopsy (SLNB) frozen section (FS) ex

46 Sentinel lymph node biopsy (SLNB) has become the gold st

47 after identification of nodal metastases by sentinel lymph node biopsy (SLNB) has been questioned.

48 iate clinical setting for the application of sentinel lymph node biopsy (SLNB) in the management of c

49 Sentinel lymph node biopsy (SLNB) is a newly developed m

50 Sentinel lymph node biopsy (SLNB) is an accurate, less i

51 ent as clinically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in th

52 Sentinel lymph node biopsy (SLNB) is currently the stand

53 Sentinel lymph node biopsy (SLNB) is the standard of car

54 500, and 800 sec/mm(2)), followed by either sentinel lymph node biopsy (SLNB) or axillary lymph node

55 ing regional lymph node evaluation by either sentinel lymph node biopsy (SLNB) or complete lymph node

56 ociated with lower- and higher-than-expected sentinel lymph node biopsy (SLNB) positivity rates and w

57 It has been validated that sentinel lymph node biopsy (SLNB) shows whether a patien

58 l recurrence rates of patients who underwent sentinel lymph node biopsy (SLNB) using radiocolloid gui

59 Sentinel lymph node biopsy (SLNB) was developed to repla

60 surgical axillary evaluation, categorized as sentinel lymph node biopsy (SLNB), axillary lymph node d

61 ospective pediatric melanoma database, using sentinel lymph node biopsy (SLNB), from 1992 to 2006, id

62 negative biopsy results underwent subsequent sentinel lymph node biopsy (SLNB), which yielded negativ

63 Final pathologic results (sentinel lymph node biopsy [SNB] or axillary lymph node

64 neoadjuvant chemotherapy could safely permit sentinel lymph node biopsy alone when the index node has

65 ruct surgeons in a standardized technique of sentinel lymph node biopsy and to educate those same sur

66 Available evidence for the role of sentinel lymph node biopsy as it applies to conjunctival

67 been done to select appropriate patients for sentinel lymph node biopsy based on multiple prognostic

68 Sentinel lymph node biopsy can be associated with delays

69 Sentinel lymph node biopsy can be performed either befor

70 Sentinel lymph node biopsy does not appear to have a sig

71 This review highlights the utility of sentinel lymph node biopsy for melanoma.

72 Patients who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer

73 of the studies in the past 2 years regarding sentinel lymph node biopsy have been concerned with iden

74 Lymphatic mapping and sentinel lymph node biopsy have been established as defi

75 review suggested that these new methods for sentinel lymph node biopsy have clinical potential but g

76 Although details of methods for sentinel lymph node biopsy have yet to be standardised,

77 d in the decision about whether to perform a sentinel lymph node biopsy in 16% of patients (67 of 420

78 rge number of surgeons capable of performing sentinel lymph node biopsy in a standardized fashion wit

79 ce for the efficacy of lymphatic mapping and sentinel lymph node biopsy in predicting prognosis, redu

80 metastatic spread undermines the utility of sentinel lymph node biopsy in this condition.

81 It is now well established that sentinel lymph node biopsy is a powerful test to predict

82 Sentinel lymph node biopsy is a reasonable alternative t

83 Sentinel lymph node biopsy is performed as a standard pr

84 t findings, it seems reasonable to recommend sentinel lymph node biopsy or at least strict regional l

85 Therefore, it may be reasonable to consider sentinel lymph node biopsy or close nodal surveillance a

86 It may therefore be reasonable to consider a sentinel lymph node biopsy or strict regional lymph node

87 Results Exercise and physical activity and sentinel lymph node biopsy reduce risk, and overweight a

88 s biopsy techniques could potentially render sentinel lymph node biopsy redundant in the future.

89 ecurrence of melanoma (16%) after a negative sentinel lymph node biopsy result was similar to that in

90 eased risk of recurrence, despite a negative sentinel lymph node biopsy result.

91 ematic review to assess three techniques for sentinel lymph node biopsy that are not radioisotope dep

92 Sentinel lymph node biopsy use and 5-year cumulative inc

93 Sentinel lymph node biopsy was adopted for the staging o

94 A sentinel lymph node biopsy was performed in 23.3% of the

95 Sentinel lymph node biopsy was performed in 73.7% of whi

96 Sentinel lymph node biopsy was performed using an increa

97 Sentinel lymph node biopsy will not identify metastases

98 inically and radiologically normal axilla is sentinel lymph node biopsy with a radioisotope and blue

99 ine patients underwent lymphatic mapping and sentinel lymph node biopsy, and 10 had a positive axilla

100 One patient had a sentinel lymph node biopsy, and 8 patients underwent hea

101 underwent intraoperative lymphatic mapping, sentinel lymph node biopsy, and inguinal femoral lymphad

102 left shoulder underwent wide local excision, sentinel lymph node biopsy, and lymph node dissection.

103 ry nodal burden, deselection of patients for sentinel lymph node biopsy, and provision of radiotherap

104 ng the appropriate selection of patients for sentinel lymph node biopsy, especially among patients wi

105 ographic characteristics, trends in usage of sentinel lymph node biopsy, rates of local and distant r

106 With the advent of sentinel lymph node biopsy, surgical methods for accurat

107 Most treatments, including sentinel lymph node biopsy, systemic therapy with taxane

108 With the advent of sentinel lymph node biopsy, the axilla can be accurately

109 e of adjuvant radiotherapy and the timing of sentinel lymph node biopsy.

110 a left lumpectomy with seed localization and sentinel lymph node biopsy.

111 All patients underwent sentinel lymph node biopsy; completion lymphadenectomy w

112 ymph-node biopsy plus axillary dissection or sentinel-lymph-node biopsy alone.

113 ngoing clinical trials will evaluate whether sentinel-lymph-node biopsy can be avoided altogether in

114 section for staging has now been replaced by sentinel-lymph-node biopsy for patients with clinically

115 Sentinel-lymph-node biopsy has been embraced as a standa

116 The introduction of sentinel-lymph-node biopsy has brought new impetus to th

117 Sentinel-lymph-node biopsy has spread so rapidly that su

118 Sentinel-lymph-node biopsy is associated with increased

119 andomly assigned women with breast cancer to sentinel-lymph-node biopsy plus axillary dissection or s

120 Refinement of the sentinel-lymph-node biopsy technique might overcome the

121 not only the indications and techniques for sentinel-lymph-node biopsy, but also lymph-node sampling

122 n was assessed in primary tumors and matched sentinel lymph nodes by a quantitative real-time PCR ass

123 Negative sentinel lymph nodes (by haematoxylin and eosin staining

124 proved survival for patients with a positive sentinel lymph node compared with patients with clinical

125 None of the three sentinel lymph nodes contained metastatic carcinoma.

126 no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases, 10-year over

127 no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases.

128 s with tumor present, but not in the hottest sentinel lymph node, counts ranged from 26% to 97% of th

129 existing nonratiometric protease sensors and sentinel lymph node detection methods, which give no inf

130 ncordance of preoperative and intraoperative sentinel lymph node detection rates.

131 Sentinel lymph node dissection (SLND) accurately identif

132 s treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axil

133 to axillary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone.

134 ed axillary dissection (TAD), which includes sentinel lymph node dissection (SLND) and selective loca

135 Sentinel lymph node dissection (SLND) has eliminated the

136 Marked variations in sentinel lymph node dissection (SLND) technique have bee

137 r overall survival for patients treated with sentinel lymph node dissection alone was noninferior to

138 ds from all patients who underwent selective sentinel lymph node dissection at the UCSF Melanoma Cent

139 the study a ureteral injury incurred during sentinel-lymph-node dissection.

140 aining both the ear and upper extremity, and sentinel lymph nodes draining different anatomic locatio

141 pecific fluorescent probe (MFP) to visualize sentinel lymph nodes during surgery, highlighting abnorm

142 duces expansion of lymphatic networks within sentinel lymph nodes, even before the onset of metastasi

143 Sentinel lymph node excision (SLNE) is considered the mo

144 actice gap exists in the surgical removal of sentinel lymph nodes, from removal of only the most radi

145 The sentinel lymph node hypothesis states that the pathologi

146 patients regarding the appropriate use of a sentinel lymph node identification and sampling procedur

147 hesia, is a safe and effective technique for sentinel lymph node identification in breast cancer pati

148 Use of sentinel-lymph-node identification has been extended to

149 planned procedures, and 418 had at least one sentinel lymph node identified.

150 INTERPRETATION: Sentinel lymph nodes identified with indocyanine green h

151 Homing of melanoma exosomes to sentinel lymph nodes imposes synchronized molecular sign

152 ence and outcomes of intramammary in-transit sentinel lymph nodes (IMSLN) from primary malignant mela

153 Tc99 is practical for the identification of sentinel lymph node in breast cancer.

154 Many of the published controversies about sentinel lymph nodes in breast cancer can be resolved by

155 Identification of sentinel lymph nodes in breast cancer is a combination o

156 Sentinel lymph nodes in breast carcinoma can be falsely

157 ific marker for clinical staging of cervical sentinel lymph nodes in head and neck SCC.

158 e intraoperative visualization of tumors and sentinel lymph nodes in real-time without disrupting nor

159 d tracer for the highly sensitive imaging of sentinel lymph nodes in solid tumor staging.

160 For selected patients with limited sentinel-lymph-node involvement, completion axillary-lym

161 d for detection and targeted excision of the sentinel lymph node is preoperative lymphoscintigraphy w

162 ians are looking for nonradioactive dyes for sentinel lymph node labeling.

163 Sentinel lymph node (LN) sampling, a technique widely us

164 number of melanocytes at both the proximal (sentinel) lymph node (LN) and the distal LN from the inj

165 In cancer patients, visual identification of sentinel lymph nodes (LNs) is achieved by the injection

166 ver, overexpression of Adm in tumors induced sentinel lymph node lymphangiogenesis and led to an incr

167 VEGF-A-overexpressing primary tumors induced sentinel lymph node lymphangiogenesis.

168 examples of their applications ranging from sentinel lymph node mapping and tumor imaging to long-te

169 )P(1-x)/InP/ZnSe were successfully used in a sentinel lymph node mapping experiment.

170 junct use of NIRF-ICG for (a) intraoperative sentinel lymph node mapping for cancer staging, (b) vide

171 se of the GAINS to guide tumor resection and sentinel lymph node mapping promises to improve surgical

172 aspiration from the iliac crests and in vivo sentinel lymph node mapping were performed during open s

173 blue dye (specifically Lymphazurin, used for sentinel lymph node mapping).

174 e quantum dots allow a major cancer surgery, sentinel lymph node mapping, to be performed in large an

175 D conjugates have been used successfully for sentinel lymph node mapping, tumor targeting, tumor angi

176 sensitivity and negative predictive value of sentinel-lymph-node mapping compared with the gold stand

177 cervical injection of indocyanine green and sentinel-lymph-node mapping followed by pelvic lymphaden

178 Sentinel-lymph-node mapping has been advocated as an alt

179 s with node-positive disease with successful sentinel-lymph-node mapping who had metastatic disease c

180 Sentinel-lymph-node mapping with complete pelvic lymphad

181 gate how the presence of neoplastic cells in sentinel lymph nodes may trigger pathways associated wit

182 FAM-labeled UNO (FAM-UNO) homed to tumor and sentinel lymph node MEMs in different cancer models: 4T1

183 he 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conse

184 but enables the direct PET visualization of sentinel lymph node metastases, eliminating the need for

185 sentinel lymph node, presence or absence of sentinel lymph node metastases, primary tumor characteri

186 ts, heparanase expression is associated with sentinel lymph node metastases.

187 phadenectomy was performed for patients with sentinel lymph node metastasis.

188 3, 2.2-cm invasive ductal carcinoma that is sentinel lymph node negative, estrogen receptor positive

189 Paraffin-embedded tissue blocks of sentinel lymph nodes obtained from patients with patholo

190 Nodal metastases were identified in the sentinel lymph nodes of 35 (97%) of these 36 patients, y

191 nd mortality, whether present in the hottest sentinel lymph node or not.

192 The number of positive sentinel lymph nodes per patient was significantly highe

193 In the SPECT/CT cohort, more sentinel lymph nodes per patient were detected than in t

194 gh ALND may be safely avoided in a subset of sentinel lymph node positive, Z0011-eligible patients, o

195 ation may improve treatment of patients with sentinel lymph node-positive melanoma.

196 I melanoma, either via clinical detection or sentinel lymph node positivity, were eligible for enroll

197 pubertal patients had a higher percentage of sentinel lymph node positivity.

198 odes removed, technetium-99m counts for each sentinel lymph node, presence or absence of sentinel lym

199 Specific technical aspects of the sentinel lymph node procedure are discussed, with emphas

200 r lymphatics-mediated melanoma metastasis to sentinel lymph node prompted by tumor-derived epidermal

201 ate methods for intraoperative assessment of sentinel lymph nodes remain a clinical priority.

202 However, sentinel lymph node removal does not necessarily extend

203 The proper evaluation of sentinel lymph nodes requires histologic and immunohisto

204 cutive patients with cutaneous melanoma with sentinel lymph nodes resected from January 5, 2004, to J

205 Sentinel lymph node resection (SNR) may reduce morbidity

206 istopathology following surgical excision of sentinel lymph node(s), which is an invasive, time consu

207 Sentinel lymph node sampling is now accepted as the stan

208 Sentinel lymph nodes set the stance of the immune system

209 include: noninvasive imaging of the breast, sentinel lymph nodes, skin, thyroid, eye, prostate (tran

210 nd abdomen in a large group of patients with sentinel lymph node (SLN) -positive melanoma.

211 In breast cancer, sentinel lymph node (SLN) biopsy allows the routine perf

212 an 20% of patients with melanoma who undergo sentinel lymph node (SLN) biopsy based on American Socie

213 entify the rate of axillary recurrence after sentinel lymph node (SLN) biopsy for breast cancer.

214 Sentinel lymph node (SLN) biopsy has shown great utility

215 may affect the false negative (FN) rate for sentinel lymph node (SLN) biopsy in breast cancer.

216 ety of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma.

217 uideline on the use of lymphatic mapping and sentinel lymph node (SLN) biopsy in staging patients wit

218 To address this potential overtreatment, sentinel lymph node (SLN) biopsy is currently being eval

219 Sentinel lymph node (SLN) biopsy provides a textbook exa

220 e recent advancements and refinements of the sentinel lymph node (SLN) biopsy technique in breast can

221 under increased scrutiny due the use of the sentinel lymph node (SLN) biopsy technique to assess the

222 Sentinel lymph node (SLN) biopsy was adopted for the sta

223 Wide excision and sentinel lymph node (SLN) biopsy was performed in all pa

224 There is no consensus regarding the need for sentinel lymph node (SLN) biopsy when regression is pres

225 urrence after a histopathologically negative sentinel lymph node (SLN) biopsy will demonstrate occult

226 utine examination of draining lymph nodes by sentinel lymph node (SLN) biopsy, the most important pre

227 ramatically changed with the introduction of sentinel lymph node (SLN) biopsy.

228 (CLND) for patients with melanoma staged by sentinel lymph node (SLN) biopsy.

229 lymphoscintigraphy on overall and bilateral sentinel lymph node (SLN) detection in cervical cancer p

230 tivariate analysis, patients with a positive sentinel lymph node (SLN) had significantly reduced mela

231 ately 17%, for which failure to identify the sentinel lymph node (SLN) is a major cause.

232 ard of care for patients with a positive (+) sentinel lymph node (SLN) is axillary dissection; howeve

233 is considered as one of the limitations for sentinel lymph node (SLN) localization.

234 rovide convenient and accurate targeting for sentinel lymph node (SLN) mapping during robotic-assiste

235 multimodality SPECT/MRI contrast agents for sentinel lymph node (SLN) mapping in vivo.

236 in patients with truncal melanoma undergoing sentinel lymph node (SLN) mapping.

237 tyrosinase mRNA in the detection of melanoma sentinel lymph node (SLN) metastases and correlated the

238 outcomes of patients with melanoma who have sentinel lymph node (SLN) metastases can be highly varia

239 Women without sentinel lymph node (SLN) metastases should not receive

240 Conclusion Women without sentinel lymph node (SLN) metastases should not receive

241 odds ratios-to calculate the probability of sentinel lymph node (SLN) metastasis for a specific pati

242 nal study to determine factors predictive of sentinel lymph node (SLN) metastasis in thin melanoma.

243 Sentinel lymph node (SLN) metastasis is the first step i

244 Sentinel lymph node (SLN) metastasis size is an importan

245 BACKGROUND AND Sentinel lymph node (SLN) metastasis size is an importan

246 of presence or absence of various factors on sentinel lymph node (SLN) metastasis was assessed using

247 s from 65 patients undergoing resection with sentinel lymph node (SLN) or level I and II ALN dissecti

248 The principal role of sentinel lymph node (SLN) sampling and ultrastaging in c

249 ed a false-negative rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chem

250 ported a 12.6% false-negative rate (FNR) for sentinel lymph node (SLN) surgery after neoadjuvant chem

251 Sentinel lymph node (SLN) surgery provides reliable noda

252 scopic surgery, the accuracy of the isotopic sentinel lymph node (SLN) technique correlated with hype

253 An accurate, intraoperative sentinel lymph node (SLN) test could decrease delayed ax

254 correlate with the probability of a positive sentinel lymph node (SLN).

255 etection of micrometastatic breast cancer in sentinel lymph nodes (SLN) and nonsentinel ALN has not b

256 ion (ALND) would enable surgeons to identify sentinel lymph nodes (SLN).

257 Sentinel-lymph-node (SLN) mapping and biopsy maintains s

258 se of the B-32 trial is to establish whether sentinel-lymph-node (SLN) resection can achieve the same

259 Sentinel-lymph-node (SLN) surgery was designed to minimi

260 Immunochemical staining of sentinel lymph nodes (SLNs) and bone marrow identifies b

261 detect the fluorescent signal emanating from sentinel lymph nodes (SLNs) approximately 2 d after inje

262 0 or T2N0 breast cancer with 1 or 2 positive sentinel lymph nodes (SLNs) are recommended to undergo a

263 for the selective assessment of nonenlarged sentinel lymph nodes (SLNs) for diagnosing metastases in

264 The evaluation of sentinel lymph nodes (SLNs) from a woman with lobular ca

265 atients with breast cancer metastasis to the sentinel lymph nodes (SLNs) generally undergo completion

266 h cT1-2N0 breast cancers and 1 to 2 involved sentinel lymph nodes (SLNs) having breast-conserving the

267 ratins (CK) is common practice in evaluating sentinel lymph nodes (SLNs) in patients with breast carc

268 Detection of micrometastases in sentinel lymph nodes (SLNs) is important for accurate st

269 etastases (clip-containing nodes) as well as sentinel lymph nodes (SLNs) may provide more accurate as

270 gional recurrence for patients with positive sentinel lymph nodes (SLNs) randomized either to axillar

271 f sentinel lymph node biopsy (SLNB) alone if sentinel lymph nodes (SLNs) were negative, SLNB with axi

272 rall survival between patients with positive sentinel lymph nodes (SLNs) who did and did not undergo

273 with breast cancer with one to two positive sentinel lymph nodes (SLNs) who undergo lumpectomy, radi

274 asured immune responses in the treated skin, sentinel lymph nodes (SLNs), and peripheral blood.

275 nt part of the mapping and identification of sentinel lymph nodes (SLNs).

276 termine whether lymphoscintigraphy (LSG) for sentinel lymph node (SNL) mapping in a woman with a brea

277 Sentinel lymph node specimens (hematoxylin-eosin negativ

278 Tumor thickness and sentinel lymph node status are the most important progno

279 Sentinel lymph node studies, positron emission tomograph

280 , a prospective, multicenter study assessing sentinel lymph node surgery after neoadjuvant chemothera

281 Sentinel lymph node surgery using both blue dye (isosulf

282 melanomas, suggesting their applicability to sentinel lymph node-targeted drug delivery.

283 showed significantly higher accumulation in sentinel lymph nodes than a control peptide.

284 Once the metastatic cells arrived at the sentinel lymph nodes, the extent of lymphangiogenesis at

285 macrophages and/or dendritic cells) in human sentinel lymph node tissues.

286 portance, in mice with metastasis-containing sentinel lymph nodes, tumors that expressed VEGF-C were

287 All sentinel lymph nodes underwent multilevel sectioning and

288 acity to delineate metastases and to map the sentinel lymph nodes via tandem PET-computed tomography

289 The sentinel lymph node was evaluated in 11 patients, result

290 urvival in patients with at least 1 positive sentinel lymph node was less than 55%.

291 Histologic ultra staging of the sentinel lymph node was prescribed.

292 Patients who had mapping of at least one sentinel lymph node were included in the primary analysi

293 A total of 1575 sentinel lymph nodes were analyzed in 475 patients.

294 d from patients with pathologically negative sentinel lymph nodes were centrally evaluated for occult

295 The margins were clear, and three sentinel lymph nodes were negative for metastasis.

296 Sentinel lymph nodes were successfully detected in all p

297 ory stimuli triggers recruitment of IPC into sentinel lymph nodes, whether the stimuli are able to di

298 ar-infrared dye show that the GAINS detected sentinel lymph nodes with 100% sensitivity.

299 e operative protocol led to resection of all sentinel lymph nodes with radioactivity greater than 10%

300 Removing only the hottest sentinel lymph node would have led to false-negative res